Skip to main content
41°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Organovo Holdings
(NQ:
ONVO
)
0.4000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organovo Holdings
< Previous
1
2
3
Next >
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
November 20, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
November 13, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
July 18, 2024
Via
Benzinga
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024
From
Organovo, Inc.
Via
GlobeNewswire
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
June 03, 2024
ONVO stock results show that Organovo Holdings beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via
InvestorPlace
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
May 09, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 09, 2024
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!
Via
InvestorPlace
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 08, 2024
From
Organovo, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 15, 2024
Via
Benzinga
Why Organovo Stock Is Up Today
April 15, 2024
Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic...
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
April 15, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
April 15, 2024
Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 12, 2024
Via
Benzinga
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023
From
Organovo, Inc.
Via
GlobeNewswire
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
November 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
November 03, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 24, 2023
Via
Benzinga
Why Logitech International Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
October 24, 2023
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares surged 91.2% to $0.2180 in pre-market trading after falling 10% on Monday.
Via
Benzinga
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Announces FXR Program
March 21, 2023
Lead Molecule Poised for Phase 2 in IBD
From
Organovo, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.